skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Peptides having reduced toxicity that stimulate cholesterol efflux

Patent ·
OSTI ID:1925053

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.

Research Organization:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
Sponsoring Organization:
USDOE; National Institutes of Health (NIH)
DOE Contract Number:
AC02-05CH11231; HL085791
Assignee:
The Regents of the University of California (Oakland, CA)
Patent Number(s):
11,434,267
Application Number:
17/016,541
OSTI ID:
1925053
Resource Relation:
Patent File Date: 09/10/2020
Country of Publication:
United States
Language:
English

References (23)

Retention of α-helical structure by HDL mimetic peptide ATI-5261 upon extensive dilution represents an important determinant for stimulating ABCA1 cholesterol efflux with high efficiency journal November 2013
Characteristics of the amino acids as components of a peptide hormone sequence book January 1976
Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases patent-application June 2011
Peptides Having Reduced Toxicity Thar Stimulate Cholesterol Efflux patent-application September 2014
Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry journal April 2010
Sustained-delivery of an apolipoproteinE–peptidomimetic using multivesicular liposomes lowers serum cholesterol levels journal February 2002
Regulation and Mechanisms of ATP-Binding Cassette Transporter A1-Mediated Cellular Cholesterol Efflux journal July 2003
Stabilized alpha helical peptides and uses thereof patent-application November 2005
Apolipoprotein E and cholesterol in aging and disease in the brain journal January 2008
Methods and reagents for modulating cholesterol levels patent-application March 2004
Cysteine-containing peptides having antioxidant properties patent October 2009
The complete genome sequence of Moorella thermoacetica (f. Clostridium thermoaceticum) journal July 2008
Helical synthetic peptides that stimulate cellular cholesterol efflux patent April 2010
Orally administered peptides synergize statin activity patent-application April 2008
Effects of l- or d-Pro incorporation into hydrophobic or hydrophilic helix face of amphipathic α-helical model peptide on structure and cell selectivity journal February 2004
Compositions and methods of use for treating cardiovascular disease patent-application September 2008
Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus journal February 1992
Protein Folding: A Glimpse of the Holy Grail? journal October 1998
Helical synthetic peptides that stimulate cellular cholesterol efflux patent-application September 2005
Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox book January 1994
Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia patent-application July 2005
The C-Terminal Lipid-Binding Domain of Apolipoprotein E Is a Highly Efficient Mediator of ABCA1-Dependent Cholesterol Efflux that Promotes the Assembly of High-Density Lipoproteins journal March 2007
The Positional Specificity of EXXK Motifs within an Amphipathic α-Helix Dictates Preferential Lysine Modification by Acrolein: Implications for the Design of High-Density Lipoprotein Mimetic Peptides journal July 2012